

## PRESS RELEASE

June 13, 2024

### **National Institute of Aging Awards Phase II Clinical Trial Funding for Neurosom Electric Sleep Therapy in Seniors with Mild Cognitive Impairment**

Neurosom's research partner, the **Brain Electrophysiology Lab (BEL)**, has received \$2.2 million in Phase II funding from the **National Institutes of Aging** to conduct an FDA-monitored clinical trial to determine if **Neurosom's Electric Sleep Therapy** can improve deep sleep and memory consolidation in seniors with Mild Cognitive Impairment (MCI).

In the Phase I feasibility study, Neurosom scientists, together with colleagues at **Wake Forest University (led by Dr. Ruth Benca)** and the **Portland Veterans Administration Research Foundation (led by Dr. Miranda Lim)**, demonstrated the ability to train seniors diagnosed with MCI to use the **Neurosom Sleep WISP** system in their homes to collect EEG (brain waves) and automatically deliver the electrical synchronization therapy to enhance deep sleep. This feasibility study was reviewed by the NIA program officer and found to be successful, thereby warranting the funding for the Phase II (pivotal) clinical trial.

**Neurosom** remains committed to testing its Electric Sleep Therapy in adults with insomnia, and plans to fund an FDA clinical trial with capital raised over the RedCrow platform.

**Neurosom** scientists provided updates on progress in the preparation and launch of the clinical trial in a Q & A webinar for investors. [Click here to watch](#)

**For investors, the NIA decision to provide non-dilutive funding for the MCI clinical trial provides important validation of the Phase I feasibility study results and advances the incremental de-risking of the investment opportunity.**